Where AI is integrating into the biotech venture funnel

AI is broadly augmenting biotech VCs’  capacity to map, source, and pressure-test investment opportunities, but the degree to which firms have invested in AI infrastructure, and their ambitions for the technology, vary widely. The question that will take years to answer is whether and how portfolios and returns will change as a result.

Like in every other sector, language models (LLMs) and agents built on top of them are rapidly becoming common tools in biotech venture. “A year and a half ago people said, ‘I wouldn’t trust anything from that.’ Now a lot of the same people have adopted AI into their workflow,”  Lux Capital’s David Yang told BioCentury...